Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the drug ...

Sanofi SNY and partner Regeneron REGN announced that the European Commission has approved Dupixent (dupilumab) for the ...

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are ...

Data from the KT-621 BROADEN2 Phase 2b AD patient trial expected to be reported by mid-2027KT-621 BREADTH Phase 2b trial in asthma on track to ...

Approval based on phase 3 studies showing Dupixent significantly reduced itch and hives at 24 weeks compared to placeboIn the EU, there are approximately 270,000 adults and adolescents aged 12 years ...

European Commission approves Sanofi & Regeneron’s Dupixent to treat moderate-to-severe chronic spontaneous urticaria: Paris Wednesday, November 26, 2025, 14:00 Hrs [IST] The Eur ...

A retrospective study found a higher prevalence of several autoimmune and inflammatory conditions, in addition to skin ...

(TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV (R) (enfortumab vedotin-ejfv), a Nectin-4 directed ...

My primary care doctor has prescribed the medication Evenity for my osteoporosis. I have been on Fosamax for about three ...

Approval based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo In the EU, there are approximately 270,000 adults and adolescents aged 12 years ...

Sanofi and Regeneron's Dupixent approved as the first targeted medicine in the EU in over a decade for chronic spontaneous urticaria Approval based on phase 3 studies showing Dupixent significantly ...

Living with early breast cancer involves more than just treatment; it's about maintaining quality of life and personal identity. Women are navigating careers, families, and daily responsibilities ...